ARCH Venture Partners X, LLC

Insider Reports History

Location
Chicago, IL
Signature
ARCH Venture Fund X, L.P. By: ARCH Venture Partners X, L.P., its General Partner By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by ARCH Venture Partners X, LLC:

Company Role Class Num Shares Value Price $ Report Date Ownership
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 12,205,379 $22,213,789 $1.82 27 Oct 2025 By ARCH Venture Fund X, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 11,886,758 $21,633,899 $1.82 27 Oct 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 6,046,907 $15,782,427 $2.61 27 Oct 2025 By ARCH Venture Fund XII, L.P.
Verve Therapeutics, Inc. 10%+ Owner Common Stock, par value $0.001 1,254,405 $12,544,050 $10.00 21 Jun 2021 ARCH Venture Fund X Overage, L.P.
Verve Therapeutics, Inc. 10%+ Owner Common Stock, par value $0.001 1,254,404 $12,544,040 $10.00 21 Jun 2021 ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Common Stock 5,527,777 $8,786,402 $1.59 20 Jul 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Common Stock 5,527,777 $8,786,402 $1.59 20 Jul 2021 By ARCH Venture Fund X Overage, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,230,300 $7,912,481 $1.27 01 Aug 2025 By ARCH Venture Fund XII, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,128,297 $7,782,937 $1.27 01 Aug 2025 By ARCH Venture Fund X, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6,128,297 $7,782,937 $1.27 01 Aug 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 2,321,566 $4,225,250 $1.82 27 Oct 2025 By ARCH Venture Fund VIII Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 1,387,228 $2,524,754 $1.82 27 Oct 2025 By ARCH Venture Fund VII, L.P.
Erasca, Inc. 10%+ Owner Series A Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series A Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X Overage, L.P.
Erasca, Inc. 10%+ Owner Series B-1 Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series B-1 Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X Overage, L.P.
Erasca, Inc. 10%+ Owner Series B-2 Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X, L.P.
Erasca, Inc. 10%+ Owner Series B-2 Preferred Stock 0 20 Jul 2021 By ARCH Venture Fund X Overage, L.P.
Verve Therapeutics, Inc. 10%+ Owner Series A-2 Convertible Preferred Stock 0 21 Jun 2021 Indirect
Verve Therapeutics, Inc. 10%+ Owner Series A Convertible Preferred Stock 0 21 Jun 2021 Indirect

Insider Reports Filed by ARCH Venture Partners X, LLC

Symbol Company Period Transactions Value $ Form Type Role Filing Time
NMRA Neumora Therapeutics, Inc. 27 Oct 2025 1 +$4,999,977 4 10%+ Owner 29 Oct 2025, 19:19
PRME Prime Medicine, Inc. 01 Aug 2025 1 +$9,999,990 4 10%+ Owner 01 Aug 2025, 19:18
MAZE Maze Therapeutics, Inc. 30 Jan 2025 0 $0 3 10%+ Owner 30 Jan 2025, 16:42
PRME Prime Medicine, Inc. 15 Feb 2024 1 +$20,000,000 4 10%+ Owner 20 Feb 2024, 17:37
NMRA Neumora Therapeutics, Inc. 08 Dec 2023 2 $0 4 10%+ Owner 12 Dec 2023, 19:52
NMRA Neumora Therapeutics, Inc. 19 Sep 2023 11 +$25,500,000 4 10%+ Owner 20 Sep 2023, 07:16
NMRA Neumora Therapeutics, Inc. 19 Sep 2023 11 +$25,500,000 4 10%+ Owner 20 Sep 2023, 07:15
NMRA Neumora Therapeutics, Inc. 14 Sep 2023 0 $0 3 10%+ Owner 14 Sep 2023, 22:29
NMRA Neumora Therapeutics, Inc. 14 Sep 2023 0 $0 3 10%+ Owner 14 Sep 2023, 22:22
PRME Prime Medicine, Inc. 24 Oct 2022 8 +$13,600,000 4 10%+ Owner 26 Oct 2022, 20:01
PRME Prime Medicine, Inc. 19 Oct 2022 0 $0 3 10%+ Owner 19 Oct 2022, 20:08
ERAS Erasca, Inc. 20 Jul 2021 8 $0 4 10%+ Owner 20 Jul 2021, 20:53
ERAS Erasca, Inc. 15 Jul 2021 0 $0 3 10%+ Owner 15 Jul 2021, 21:06
VERV Verve Therapeutics, Inc. 21 Jun 2021 6 $0 4 10%+ Owner 23 Jun 2021, 16:29